Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2017-003076-31-DE
EUCTR2017-003076-31-DE
Active, not recruiting
Phase 1

An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment with or without second surgery. - VXM01 plus Avelumab combination study in progressive glioblastoma

VAXIMM GmbH0 sites30 target enrollmentApril 30, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsBavencio

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
VAXIMM GmbH
Enrollment
30
Status
Active, not recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 30, 2018
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\.Subjects who are able to understand and follow instructions during the trial
  • •2\.Ability and willingness to give written informed consent, signed and dated
  • •3\.Male or female subjects. Female subjects must be post\-menopausal for at least 2 years or surgically sterile
  • •4\.Age \=18 years
  • •5\.Histologically diagnosed intracranial supratentorial malignant glioma (contrast\-enhancing glioblastoma WHO Grade IV)
  • •6\.Evidence of tumor progression by RANO criteria following at least one prior therapy regimen that must have contained radiation and chemotherapy with temozolomide, as measured by MRI
  • •?Raditotherapy must have been completed at least 3 months prior to the inclusion visit
  • •7\.Candidates for a tumor reoperation (for the resectable arm \[n\=6] only)
  • •?Neurosurgical intervention should be postponable for 30 days
  • •8\.Adequate bone marrow function including: Absolute neutrophil count (ANC) \=1,500/mm3 or \=1\.5 x 109/L; Platelets \= 100,000/mm3 or \=100 x 109/L; Hemoglobin \= 9 g/dL (may have been transfused); INR \<1\.5x ULN. Subjects with documented benign cyclical neutropenia are allowed if WBC count is \= 1\.5 × 109/L with absolute neutrophil count \= 1\.0 × 109/L and appropriate hematology parameters: leukocytes \=4\.0 x 109 / L, lymphocytes \=0\.6 x 109/L

Exclusion Criteria

  • •1\.Cardiovascular disease:
  • •\- uncontrolled hypertension
  • •\- arterial thromboembolic event within 6 m before trial entry
  • •2\.Congestive heart failure NY Heart Association grade III to IV
  • •3\.Serious ventricular arrhythmia requiring medication and arrhythmias requiring ICD
  • •4\.Clinically significant peripheral artery disease \> grade 2b according to Fontaine
  • •5\.History of relevant intracranial hemorrhage
  • •6\.Hemoptysis within 6 m before trial entry
  • •7\.Known oesophageal varices
  • •8\.Upper or lower gastrointestinal bleeding within 6 m before inclusion

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment, with or without second surgery.
NL-OMON48738VAXIMM GmbH9
Active, not recruiting
Phase 1
An early phase clinical study of VXM01 in combination with avelumab in patients with brain cancer following standard treatment.Progressive glioblastoma (WHO grade IV)MedDRA version: 20.0 Level: PT Classification code 10018336 Term: Glioblastoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2017-003076-31-NLVAXIMM GmbH30
Active, not recruiting
Phase 1
An open-label, phase I/II multicenter clinical trial of NECVAX-NEO1 as add-on to first-line neoadjuvant anti-PD-1 monoclonal antibody therapy in patients with triple-negative breast cancer
CTIS2024-512520-11-00EC Bio Therapeutics GmbH8
Active, not recruiting
Phase 1
An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients with Solid Tumors (NECVAX-NEO1-02-INT).Advanced solid tumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104Therapeutic area: Not possible to specify
CTIS2024-511212-24-00EC Bio Therapeutics GmbH40
Completed
Not Applicable
A Multicenter, Open-label, Phase I/II Clinical Trial of Intraperitoneal Paclitaxel and Oral S-1 and Intravenous Oxaliplatin Combination Therapy in Patients with Advanced ll
KCT0004670Myungmoon Pharm53